The FDA has approved Eli Lilly and Company Reyvow (lasmiditan) pill for the treatment of acute (active, but short-lived) migraine with or without aura in adult patients. It should be noted that the drug is not intended for the prophylactic treatment of migraine.
The efficacy of lasmiditan was evaluated in two randomized, double-blind, placebo-controlled trials in 3177 adult patients with a history of migraine with or without aura. According to the results obtained, the number of patients who, two hours after taking Reyvow, disappeared migraine symptoms, including nausea, sensitivity to sound and light, was significantly higher than when taking placebo.
The most common side effects associated with taking lasmiditan were dizziness, fatigue, paresthesia, and sedation. It should be noted that the use of lasmiditan affects the ability to drive a vehicle, therefore it is not recommended to drive a car for at least eight hours after taking the drug.